Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (851-860 of 1,298) with videos related to

Pageof 130
Sort By:
Cancer Research|November 8, 2014
Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activationTae Hoon Kim, Jung-Yoon Yoo, Hong Im Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinomaSarah Wheeler, Doris R Siwak, Raymond Chai, et al.
The Journal of Biological Chemistry|January 30, 2003
Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptorYutaka Hasegawa, James R Erickson, Graham J Goddard, et al.
Communications Biology|December 12, 2022
L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovaryKai Doberstein, Rebecca Spivak, Hunter D Reavis, et al.
Molecular Cancer Therapeutics|January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessClaudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Oncotarget|October 27, 2015
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayAzadeh Cheraghchi-Bashi, Christine A Parker, Ed Curry, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 21, 2022
Spasticity Management Teams, Evaluations, and Tools: A Canadian Cross-Sectional SurveyPatricia B Mills, Chetan P Phadke, Chris Boulias, et al.
Human Molecular Genetics|March 18, 2005
Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidasePhilippa B Mills, Robert A H Surtees, Michael P Champion, et al.
NPJ Systems Biology and Applications|June 27, 2017
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmDaniel J McGrail, Curtis Chun-Jen Lin, Jeannine Garnett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancerAna M Gonzalez-Angulo, Katherine Stemke-Hale, Shana L Palla, et al.
Pageof 130

Showing results (851-860 of 1,298) with videos related to

Sort By:
Pageof 130
Cancer Research|November 8, 2014
Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activationTae Hoon Kim, Jung-Yoon Yoo, Hong Im Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinomaSarah Wheeler, Doris R Siwak, Raymond Chai, et al.
The Journal of Biological Chemistry|January 30, 2003
Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptorYutaka Hasegawa, James R Erickson, Graham J Goddard, et al.
Communications Biology|December 12, 2022
L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovaryKai Doberstein, Rebecca Spivak, Hunter D Reavis, et al.
Molecular Cancer Therapeutics|January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessClaudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Oncotarget|October 27, 2015
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayAzadeh Cheraghchi-Bashi, Christine A Parker, Ed Curry, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 21, 2022
Spasticity Management Teams, Evaluations, and Tools: A Canadian Cross-Sectional SurveyPatricia B Mills, Chetan P Phadke, Chris Boulias, et al.
Human Molecular Genetics|March 18, 2005
Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidasePhilippa B Mills, Robert A H Surtees, Michael P Champion, et al.
NPJ Systems Biology and Applications|June 27, 2017
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmDaniel J McGrail, Curtis Chun-Jen Lin, Jeannine Garnett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancerAna M Gonzalez-Angulo, Katherine Stemke-Hale, Shana L Palla, et al.
Pageof 130